Compare Bills

Primary Sponsor

Last Action

Ref To Com On Rules and Operations of the Senate2025-05-07

Vote Breakdown

Plain Language Summary

This bill requires health insurance plans in North Carolina to cover biomarker testing (blood tests and tissue analysis that detect disease markers) when supported by medical evidence, such as FDA approval or national clinical guidelines. It also applies these same coverage requirements to North Carolina's Medicaid program and protects individuals from insurance discrimination based on biomarker test results.

Arguments in Favor

• •Supporters argue this bill improves early disease detection and diagnosis, particularly for dementia, allowing patients to access treatment and support services sooner.
• •They contend that biomarker testing can reduce overall healthcare costs by enabling earlier intervention and better disease management.
• •Proponents also emphasize that the bill protects patients from genetic discrimination by preventing insurers from denying coverage or raising premiums based on biomarker test results.

Arguments Against

• •Opponents may be concerned about increased insurance costs, as mandatory coverage of biomarker testing could raise premiums for all enrollees.
• •They might argue that some biomarker tests lack sufficient clinical evidence and question whether the bill's broad definition adequately limits coverage to only medically necessary tests.
• •Some may also worry about implementation challenges for insurers and the state Medicaid program in determining which tests meet the evidence standards outlined in the bill.